TEIXOBACTIN - A GAME CHANGER ANTIBIOTIC

Abstract

Ateam of scientist under the supervision of Kim Lewis from Northeastern University has discovered a novel antibiotic called Teixobactin, which kills the bacteria by inhibiting them from building their outer protein envelop. The bacterial resistance interference are key challenges to the global health. Teixobactin shows exceptional antibacterial activities against the range of pathogenic bacteria viz S.Aureus and Mycobacterium Tuberculosis. It is bactericidal and has many mode of operation, however it is one of the most important contribution in the modernization of medicine. However, the increase in Antibiotic resistance is at alarming rate and the ability of patient care through antibiotics is a challenge nowadays increment in Antibiotics resistance is among the top public health threats in the century 21". According to the Centers for Disease Control and Prevention (CDCP), around 23 thousand peoples die in every year in United States of America (USA) due to Antibiotic resistance. Whenever the patient is administered with an antibiotic the condition of the patient does not improve due to which more than 2 million people are sickened. The increase in Antibiotic resistance is much greater than the increase in epidemic diseases such as Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome (Al DS) or Ebola Virus Disease. The cost of human Antibiotic resistance crisis is estimated to be 300 million mortalities collectively by 2050. And it will also be the cause of declining graph of global economy of around $100 trillion. Production of new antibiotics in the 21" century seems to be difficult task to deal Teixobactin comes under new class of antibiotics. It is the first new antibiotic that is being isolated from bacteria after 30 years. After teixobactin's isolation from the soil full of bacteria, another novel class of antibiotics are discovered known as Malacidine, which was revealed later in 2018